Low-dose endoxifen shows breast density reductions with fewer side effects in prevention study
A Karolinska Institutet study found that daily low-dose endoxifen reduced mammographic breast density by 19% to 26% in healthy premenopausal women over six months, with fewer side effects than standard tamoxifen.
- In a six-month study of 240 healthy premenopausal women, 1 mg and 2 mg daily endoxifen both reduced mammographic breast density versus placebo.
- Average density reductions were 19% at 1 mg and 26% at 2 mg, compared with prior data showing about 18.5% reduction with 20 mg tamoxifen.
